EGFR and non-small cell lung carcinoma: Treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib has led to significant clinical improvement in certain patients with advanced non-small-cell lung cancer (NSCLC), particularly those of Asian descent, non-smokers and those with adenocarcinoma (1–4).